Isomorphic Labs, Google’s A.I. Drug Business, Raises $600 Million The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as ...

Under the agreement, Isomorphic is also eligible to receive up to $1.7bn in “performance-based milestones.” The company also signed a similar collaboration with Swiss biotech Novartis.

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical programs, and accelerate disease research.

Isomorphic’s deals come as Google faces fierce competition on the development of AI software from the likes of Microsoft-backed OpenAI and smaller start-ups such as Anthropic and Cohere.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital ...

> Isomorphic Labs is preparing to launch human trials of AI-designed drugs. > Mission: faster, cheaper, more accurate drug discovery using AI. AI will make the world a better place.

Isomorphic Labs, the drug discovery start-up spun out of Google’s DeepMind artificial intelligence unit, has raised $600mn in its first external funding round, as investors bet on the potential ...